Health and Healthcare

Amgen : AMGN

All Amgen Articles

708 Articles

Lee Jackson | Oct 13, 2014 at 8:40 AM EDT

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

Rising trends in prescriptions and higher, yet beatable increases in earnings have set the table for what the UBS biotech…

Chris Lange | Oct 10, 2014 at 10:10 AM EDT

Short Interest in Biotech Becomes Company Specific

The short interest data are out for the end of September settlement date, and 24/7 Wall St. has reviewed the…

Lee Jackson | Sep 29, 2014 at 8:30 AM EDT

3 Likely Biotech Buyout Candidates

A new research report from the analysts at Cowen sees a potential wave of biotech deals, some of which could…

Jon C. Ogg | Sep 25, 2014 at 10:50 AM EDT

Short Sellers Make Moves in Key Biotech Stocks

Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the most…

247alex | Sep 25, 2014 at 6:12 AM EDT

10 Companies Cutting the Most Jobs

Through August, planned job cuts were slightly lower than they were during the first eight months of 2013. In all,…

Chris Lange | Sep 11, 2014 at 9:20 AM EDT

Short Sellers Remain Vigilant Against Biotechs

Short sellers are often active in biotech stocks, and we have seen some excessive short interest activity in the latest…

Lee Jackson | Sep 9, 2014 at 8:30 AM EDT

Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015

A new report from the biotech team at Deutsche Bank fields questions from clients asking for specific stocks to buy…

Chris Lange | Aug 27, 2014 at 10:25 AM EDT

Rising Short Interest in Biotech Stocks

Short sellers might be inclined to bet against biotech companies because of their volatile behavior on the charts.

Lee Jackson | Aug 18, 2014 at 9:00 AM EDT

RBC’s Top Quintile Quantitative Portfolio Stocks to Buy Now

ThinkstockMost firms we cover on Wall Street have quantitative strategies for their clients, and often they use similar formulas to…

Jon C. Ogg | Aug 1, 2014 at 10:20 AM EDT

Do Layoffs in Biotech Send the Right Message?

This week's layoff announcement by Amgen may have investors and the public starting to rethink what "being a biotech company"…

Lee Jackson | Jul 28, 2014 at 8:55 AM EDT

5 Huge Biotech Catalysts Right Around the Corner for Top Stocks

ThinkstockA brand new research report from RBC highlights more than 50 biotech event catalysts that are on the horizon. These are…

Lee Jackson | Jul 21, 2014 at 8:25 AM EDT

Deutsche Bank Raises Price Targets on Top Biotech and Health Care Stocks

New research reports from the biotech, health care and medical device teams at Deutsche Bank raise price targets on three…

Lee Jackson | Jul 16, 2014 at 10:15 AM EDT

4 Top Biotechs Expected to Beat Earnings Expectations

In a research note, Leerink analysts mentioned four specific top biotech names that may have the ability to beat current…

Lee Jackson | Jul 9, 2014 at 8:40 AM EDT

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

In a new research report, UBS analysts are very positive on some top biotech stocks before second-quarter earnings numbers hit…

Jon C. Ogg | Jun 19, 2014 at 2:05 PM EDT

Will Celgene Trigger Other Biotech Stock Splits?

Celgene has decided to join the stock split game. Even though stock splits change nothing fundamentally, 24/7 Wall St. would…

1 … 28 29 30 31 32 … 48

Amgen : AMGN

All Amgen Articles

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

Short Interest in Biotech Becomes Company Specific

3 Likely Biotech Buyout Candidates

Short Sellers Make Moves in Key Biotech Stocks

10 Companies Cutting the Most Jobs

Short Sellers Remain Vigilant Against Biotechs

Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015

Rising Short Interest in Biotech Stocks

RBC’s Top Quintile Quantitative Portfolio Stocks to Buy Now

Do Layoffs in Biotech Send the Right Message?

5 Huge Biotech Catalysts Right Around the Corner for Top Stocks

Deutsche Bank Raises Price Targets on Top Biotech and Health Care Stocks

4 Top Biotechs Expected to Beat Earnings Expectations

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

Will Celgene Trigger Other Biotech Stock Splits?

If Social Security Cuts Benefits, Here’s Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account

AI Architect Earning $1.1M/Year Almost Took on $550K in Debt to Dodge Taxes: ‘I Have No Idea What That Business Is’

If Social Security Cuts Benefits, Here's Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account

If Social Security Cuts Benefits, Here’s Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account

Amgen : AMGN

All Amgen Articles

UBS Very Positive on Top Biotech Stocks Ahead of Earnings

Short Interest in Biotech Becomes Company Specific

3 Likely Biotech Buyout Candidates

Short Sellers Make Moves in Key Biotech Stocks

10 Companies Cutting the Most Jobs

Short Sellers Remain Vigilant Against Biotechs

Deutsche Bank’s 4 Top Biotech Stocks to Buy for This Year and 2015

Rising Short Interest in Biotech Stocks

RBC’s Top Quintile Quantitative Portfolio Stocks to Buy Now

Do Layoffs in Biotech Send the Right Message?

5 Huge Biotech Catalysts Right Around the Corner for Top Stocks

Deutsche Bank Raises Price Targets on Top Biotech and Health Care Stocks

4 Top Biotechs Expected to Beat Earnings Expectations

UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings

Will Celgene Trigger Other Biotech Stock Splits?

If Social Security Cuts Benefits, Here’s Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account

AI Architect Earning $1.1M/Year Almost Took on $550K in Debt to Dodge Taxes: ‘I Have No Idea What That Business Is’

Featured Reads

If Social Security Cuts Benefits, Here's Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account